CALLE DOCTOR FLEMING, 51 | 28036 MADRID, SPAIN
+34 91 3459395 | +44 (0) 20 3951 8071
info@oxonepi.com

NEWS & EVENTS

THANKS FOR SHARING YOUR TIME WITH OXON AT ICPE2022

Thanks for your time at the 38th International Conference on PharmacoEpidemiology, ICPE 2022. August 24-28, 2022 | Bella Center Copenhagen | Copenhagen, Denmark At OXON Epidemiology, we would like to thank you for visiting our booth at ICPE 2022 and contributing to our success during the event. Thanks for your interest in our services during the event…
Read more

ICPE2022

OXON AT ICPE Conference – 24-28 August2022

OXON’s real-world studies at the 38th International Conference on PharmacoEpidemiology, ICPE 2022.  Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community August 24-28, 2022 | Bella Center Copenhagen | Copenhagen, Denmark At OXON we are excited to be supporting ICPE 2022 as an exhibitor, presenting our capabilities and research during this in-person event for scientific and…
Read more

OXON Masterclasses

OXON’s FREE LIVE ONLINE REAL WORLD MASTERCLASS SERIES 2022-2023

FREE LIVE REAL WORLD MASTERCLASS SERIES 2022-2023 ‘How to ensure success and avoid pitfalls in Real World studies by Understanding Healthcare in Europe and Asia’ Dates: Monthly starting in February 2022 | Time: 5pm CET | 4pm UK | 11am EST | 8am PST OXON is resuming the series of masterclasses on real world evidence…
Read more

ICPE2021

OXON at ICPE21 All Access Virtual Conference on 23-25 August, 2021

OXON is delighted to be supporting ICPE again this year with a virtual exhibition booth from which we will be happy to speak with you about our specialisation in data collection, secondary data and hybrid real world studies, pragmatic trials and meta-analyses to help plan, design and implement RWE for safety, market access and drug development.

Cholesterol-dementia cohort study

Lancet study shows cholesterol in middle-age ‘linked to Alzheimer’s more than 10 years later’

The study, published in Lancet Healthy Longevity, suggests that high levels of cholesterol in middle-age are associated with an increased risk of developing dementia and Alzheimer’s disease. The retrospective cohort study ‘Blood cholesterol and risk of dementia in a retrospective cohort of over 1.8 million people over two decades’, presented at the 35th International Conference…
Read more

RWE & Trials Live Masterclass Session 4: ‘Individualizing Benefit Risk’

RWE Masterclass 4: ‘Individualizing Benefit Risk’ Session 4: ‘Individualizing Benefit Risk’, will take place on Wednesday, 16 June 2021 at 5 pm CEST MORE INFORMATION|REGISTER HERE   SUMMARY: Conventional methods of benefit-risk overly focus on overall results; subgroups have limitations, and the relative importance of events may not be considered. Individualizing benefit-risk more precisely would…
Read more

OXON Masterclass Series- Session3

RWE & Trials Live Masterclass Session 3: ‘Non-randomised Comparative Studies’

RWE Masterclass 3: ‘Non-randomised comparative studies’ Non-randomised comparative studies will be the main topic of the next session of our Real-World Evidence Masterclass Series. This Masterclass mini-series are meant for attendees to learn about perspectives on RWE studies with the help of two experts in this particular field: Professor Stuart Pocock, renewed trialist and statistician, and…
Read more

Masterclass 2 Propensity Scores

RWE & Trials Live Masterclass Session 2: ‘The Tyranny of Propensity Scores’

RWE Live Masterclass 2: ‘The Tyranny of Propensity Scores’ Propensity Scores will be the main topic of the next session of our Real-World Evidence Masterclass Series. This Masterclass mini-series are meant for attendees to learn about perspectives on RWE studies with the help of two experts in this particular field: Professor Stuart Pocock, renewed trialist…
Read more

RWE Masterclass

OXON’s RWE & Trials Free Live Masterclass Series 2021

Real-World Evidence & Trials Masterclass Series 2021  OXON Epidemiology will be hosting a Real-World Evidence Masterclass Series for all professionals interested in learning about the role of Real-World Data studies and their pros and cons compared with trials. Real-World Evidence (RWE) is a key opportunity to better understand the diseases and patient needs. Besides, all…
Read more

""

OXON wins first prize for a spotlight poster at ICPE20 All Access Virtual Conference

OXON is delighted to be supporting ICPE again this year with a virtual exhibition booth from which we will be happy to speak with you about our specialisation in data collection, secondary data and hybrid real world studies, pragmatic trials and meta-analyses to help plan, design and implement RWE for safety, market access and drug development.